Arthur Allen, Gregory Piazza, Margaret Fang/LinkedIn
Sep 12, 2025, 15:44
Long-Term Apixaban Use for Provoked VTE: Focus on HI-PRO Trial by Arthur Allen, Margaret Fang and Gregory Piazza
Anticoagulation Forum shared on LinkedIn:
”Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
Faculty:
Arthur Allen, PharmD, CACP – Salt Lake City Va Health Care System
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register here.
Stay informed on all webinars and seminars in the field of thrombosis with Hemostasis Today.
-
Sep 22, 2026, 04:43Michael Cahillane: Highlights From BBTS2026 in Glasgow
-
Sep 22, 2026, 04:15Wolfgang Miesbach: First AAV Gene Therapy Data in Adolescents With Haemophilia B
-
Sep 22, 2026, 04:03Emmanuel J Favaloro: 100 Years of VWD – A Special Virtual Issue
-
Sep 22, 2026, 03:31Mostafa Elshazly: How Is Humidification Used During Non Invasive Ventilation?
-
Sep 22, 2026, 03:05Sumyea Kabir: Jehovah’s Witnesses Update Their Position on Blood Components
-
Sep 22, 2026, 02:33Gerardo Moscatelli: The Spike Protein Cascade – From Endothelial Binding to Vascular Collapse
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight
-
Sep 21, 2026, 20:54Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH